Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
We conducted a phase 3, randomized, open-label study involving patients infected with HCV genotype 1 who had not had a sustained virologic response after treatment with peginterferon and ribavirin, with or without a protease inhibitor.
Immunomodulatory role of the hepatocyte during HCV infection
PMC3757554 : Hepatitis C virus (HCV) is remarkable at disrupting human immunity to establish chronic infection. Accumulation of regulatory T cells (Tregs) and up-regulation of inhibitory signaling pathways (such as Tim-3/Gal-9) play pivotal roles in suppressing antiviral effector T cells (Teffs) that are essential for viral clearance.
Approaches to hepatitis C treatment and cure using NS5A inhibitors
PMC3949698 : Recent progress in the understanding of hepatitis C virus (HCV) biology and the availability of in vitro models to study its replication have facilitated the development of direct-acting antiviral agents (DAAs) that target specific steps in the viral replication cycle.
PMC3915892 : Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy.
The experiences with therapy in children with chronic hepatitis C are based on earlier and continuing data from adult trials.
In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with HCV genotype 3 infection.